

Canada Cardiovascular Drugs Market, By Drug Classification (Branded, Generic), By Disease Indication (Hypertension, Coronary Artery Disease, Hyperlipidaemia, Arrhythmia, Others), By End User (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Others), By Region, Competition Forecast & Opportunities, 2028

Market Report | 2023-08-01 | 74 pages | TechSci Research

AVAILABLE LICENSES:

- Single User License \$3500.00
- Multi-User License \$4500.00
- Custom Research License \$7500.00

Report description:

Canada Cardiovascular Drugs Market is anticipated to witness impressive growth during the forecast period. This can be ascribed to the growing burden of cardiovascular diseases along with risk factors such as diabetes, hypertension etc. Also, growing adoption of minimally invasive procedures is expected to create a lucrative growth during the forecast period. Similarly, technologies used in the development of cardiology devices have significantly increased the demand for devices during the forecast period. Another trend is the shift towards personalized medicine, where drugs are tailored to individual patients based on their genetic makeup and other individual characteristics. This approach has the potential to improve the efficacy of drugs and reduce the risk of side effects. For instance, as per the data published by the Heart and Stroke Foundation Canada in February 2022, 750,000 people had a heart failure and 100,000 people are diagnosed with this incurable condition each year in Canada. Growing Prevalence of Cardiovascular Diseases

The increasing prevalence of cardiovascular diseases is a major driver of growth in the Canadian Cardiovascular Drugs Market. Cardiovascular diseases are a leading cause of death in Canada, and the aging population and unhealthy lifestyle habits, such as poor diet and lack of exercise, are contributing to the rising prevalence of these diseases. This includes devices such as implantable cardioverter defibrillators (ICDs), pacemakers, cardiac resynchronization therapy (CRT) devices, and transcatheter heart valves. The Canadian healthcare system is investing heavily in the diagnosis and treatment of cardiovascular diseases. This is driving the adoption of advanced technologies and treatments, including the use of remote patient monitoring and minimally invasive procedures. This, in turn, is driving the demand for Cardiovascular Drugs that are designed to support these advanced treatments. Furthermore, the Canadian government is promoting the growth of the Cardiovascular Drugs Market by supporting research and development in this field. For instance, the Canadian Institutes of Health Research (CIHR) has invested in several

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

initiatives aimed at improving cardiovascular health, including the development of new devices and treatments. For example, the Canadian Cardiovascular Society has launched several initiatives to improve access to cardiovascular drugs and promote healthy lifestyle choices.

Increasing healthcare expenditure

Increasing healthcare expenditure is another key factor driving the growth of the Canada Cardiovascular Drugs Market. The Canadian government is investing in significant resources in healthcare, including cardiovascular care. This has led to improved access of cardiovascular drugs for patients. The Canadian healthcare system is publicly funded, and the government spends a significant proportion of its budget on healthcare. The government's focus on healthcare spending has led to increased access to cardiovascular drugs for patients, particularly for those with low incomes or without private insurance. The government has implemented several programs and policies to improve cardiovascular care, such as the Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) initiative, which aims to improve the quality of cardiovascular care in Canada. The growing prevalence of cardiovascular diseases in Canada is leading to a higher demand for healthcare services, including cardiovascular drugs. The government is investing in healthcare infrastructure and services to meet this growing demand.

Growing adoption of combination therapies

The growing adoption of combination therapies is a key factor influencing the growth of the Canada cardiovascular drugs market. Combination therapies are drug regimens that combine two or more drugs with different mechanisms of action to achieve a more comprehensive treatment approach. Combination therapies are increasingly being used in the management of cardiovascular diseases in Canada. This is due to the recognition that single-drug therapies may not be effective in achieving optimal outcomes in some patients. Combination therapies can help to improve the efficacy of treatment, reduce adverse effects, and improve patient adherence. For example, combination therapy for hypertension may include drugs from different classes, such as diuretics, ACE inhibitors, and calcium channel blockers, to achieve optimal blood pressure control.

Combination therapy for heart failure may include drugs that target different pathways, such as angiotensin receptor blockers and beta-blockers, to improve cardiac function. The growing adoption of combination therapies is driven by the availability of newer drugs and the increasing understanding of the pathophysiology of cardiovascular diseases. These combination therapies can offer commercial benefits for pharmaceutical companies as well as extend the patent life of drugs and increasing revenue of the company. Combination therapies can be more cost-effective for patients by reducing the need for multiple prescriptions and medical visits. led to the development of more targeted and effective combination therapies.

Growing Advancements in drug development

Advancements in technology are a major factor influencing the growth of the Canada Cardiovascular Drugs Market. The development of new technologies has led to the discovery of new drugs and improved treatment options for cardiovascular diseases. In addition, technology has made it possible to deliver cardiovascular drugs more effectively and efficiently, improving patient outcomes and reducing healthcare costs. One of the key technological advancements in the cardiovascular drugs market is the development of personalized medicine.

Personalized medicine is an approach that involves tailoring treatment to an individual's genetic and molecular profile. This approach can lead to more effective treatment options and reduce the risk of adverse events. Advancements in genetic testing and biomarker identification have made it possible to identify patients who are most likely to benefit from specific drugs, improving treatment outcomes.

Another area of technological advancement in the cardiovascular drugs market is drug delivery systems. Drug delivery systems can improve the efficacy of cardiovascular drugs by delivering them directly to the site of action. For example, drug-eluting stents can be used to deliver drugs to the site of a blockage in the coronary artery, reducing the risk of restenosis. Inhalation therapy is being developed for the treatment of pulmonary hypertension, which can improve drug delivery to the lungs. Advancements in digital health technologies, such as wearables, mobile health apps, and telemedicine, are impacting the Cardiovascular Drugs Market. These technologies can help to improve patient adherence to medication regimens and provide real-time monitoring of vital signs, allowing for early detection of cardiovascular events.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Growing Demand for Personalized Medicine Drives the Growth of the Market

Personalized medicine is a key driver of growth in the Canada Cardiovascular Drugs Market. Personalized medicine involves the use of a patient's genetic and molecular profile to tailor treatment to their specific needs, leading to more effective and targeted therapies. This approach has significant potential in the treatment of cardiovascular diseases, where individual variations in response to treatment can be significant. A major area of significant impact of personalized medicines is the treatment of dyslipidemia, which will drive the growth of the market over the years.

Genetic testing can identify patients with familial hypercholesterolemia, a genetic condition that results in high levels of low-density lipoprotein cholesterol (LDL-C). These patients are often unresponsive to traditional lipid-lowering therapies and require more aggressive treatment with statins or other cholesterol-lowering drugs. Another area where personalized medicine is making a difference is in the treatment of hypertension. Genetic testing can help identify patients who are more likely to respond to certain types of antihypertensive drugs, such as ACE inhibitors or beta-blockers. This can help clinicians to select the most effective treatment regimen for each patient, leading to better blood pressure control and reduced risk of cardiovascular events. Personalized medicines have an impact on the development of new cardiovascular drugs. Genetic testing and biomarker identification can help identify new drug targets and facilitate the development of more targeted and effective therapies.

Increasing Awareness about novel drugs and therapies propel the growth of the market.

Increasing awareness of cardiovascular diseases among aging population and the importance of early detection and treatment is expected to drive the growth of Canadian cardiovascular drugs market over the years. As more people become aware of the risks associated with cardiovascular diseases, they are seeking out preventive measures and treatment options, which is driving demand for cardiovascular devices. Several factors are driving awareness of cardiovascular diseases, including public health campaigns, media coverage, and increasing prevalence of these diseases. The Canadian government and non-profit organizations have launched public health campaigns to raise awareness about the risk factors associated with cardiovascular diseases, such as high blood pressure, smoking, and poor diet. Additionally, awareness has led to increased demand for innovative treatment options, such as minimally invasive procedures and implantable devices, novel drugs. These devices include pacemakers, implantable defibrillators, heart valves, etc. Companies that offer innovative and effective treatment options are experiencing increased demand for their products. Additionally, companies that specialize in diagnostic devices and remote monitoring technologies are benefiting from the growing demand for early detection and proactive management of cardiovascular diseases.

Recent Development

☐ In 2018, the drug Evolocumab (brand name Repatha) was approved by Health Canada for the treatment of high cholesterol. Repatha is a PCSK9 inhibitor that works to lower LDL-C levels.

☐ In 2019, the drug Rivaroxaban (brand name Xarelto), was approved by Health Canada for the treatment of chronic coronary or peripheral artery disease. Xarelto is an anticoagulant that works to prevent blood clots and reduce the risk of stroke.

☐ In 2020, the drug Vericiguat (brand name Verquvo) was approved by Health Canada for the treatment of heart failure with reduced ejection fraction. Verquvo is a guanylate cyclase stimulator that works to increase the production of cyclic guanosine monophosphate (cGMP), leading to vasodilation and improved cardiac function.

Market Segmentation

The Canada Cardiovascular Drugs Market can be segmented by drug classification, disease indication, end user, and region. Based on drug classification, the market can be divided into branded and generic. Based on disease indication, the market can be segmented into hypertension, coronary artery disease, hyperlipidaemia, arrhythmia, and others. Based on end user, the market can be grouped into hospital pharmacies, online pharmacies, retail pharmacies, and others.

Market Players

Bristol-Myers Squibb Canada Co, Pfizer Canada., Janssen Pharmaceuticals, Inc., Novartis Pharmaceuticals Canada Inc, Merck & Co Inc., AstraZeneca Canada Inc., Sanofi-Aventis Canada Inc., Gilead Sciences Canada, Inc., Hoffmann-La Roche Limited. are some of

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

the leading players operating in the Canada Cardiovascular Drugs Market.

Report Scope:

In this report, the Canada Cardiovascular Drugs market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

□□Canada Cardiovascular Drugs Market, By Drug Classification:

o□Branded

o□Generic

□□Canada Cardiovascular Drugs Market, By Disease Indication:

o□Hypertension

o□Coronary Artery Diseases

o□Hyperlipidaemia

o□Arrhythmia

o□Others

□□Canada Cardiovascular Drugs Market, By End User:

o□Hospital Pharmacies

o□Online Pharmacies

o□Retail Pharmacies

o□Others

□□Canada Cardiovascular Drugs Market, By Region:

o□Ontario region

o□Quebec region

o□Alberta region

o□British Columbia region

o□Saskatchewan and Manitoba region

o□Rest of Canada

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present Canada Cardiovascular Drugs Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

□□Detailed analysis and profiling of additional market players (up to five).

Table of Contents:

1.□Product Overview

1.1.□Market Definition

1.2.□Scope of the Market

1.2.1.□Markets Covered

1.2.2.□Years Considered for Study

1.2.3.□Key Market Segmentations

2.□Research Methodology

2.1.□Objective of the Study

2.2.□Baseline Methodology

2.3.□Key Industry Partners

2.4.□Major Association and Secondary Types

2.5.□Forecasting Methodology

2.6.□Data Triangulation & Validation

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 2.7.□Assumptions and Limitations
- 3.□Executive Summary
- 3.1.□Overview of the Market
- 3.2.□Overview of Key Market Segmentations
- 3.3.□Overview of Key Market Players
- 3.4.□Overview of Key Regions/Countries
- 3.5.□Overview of Market Drivers, Challenges, and Trends
- 4.□Voice of Customer
- 5.□Canada Cardiovascular Drugs Market Outlook
- 5.1.□Market Size & Forecast
- 5.1.1.□By Value
- 5.2.□Market Share & Forecast
- 5.2.1.□By Drug Classification (Branded v/s Generic)
- 5.2.2.□By Disease Indication (Hypertension, Coronary Artery Disease, Hyperlipidaemia, Arrhythmia, Others)
- 5.2.3.□By End User (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Others)
- 5.2.4.□By Region
- 5.2.5.□By Company (2022)
- 5.3.□Market Map
- 6.□Canada Branded Cardiovascular Drugs Market Outlook
- 6.1.□Market Size & Forecast□
- 6.1.1.□By Value
- 6.2.□Market Share & Forecast
- 6.2.1.□By Disease Indication
- 6.2.2.□By End User
- 7.□Canada Generic Cardiovascular Drugs Market Outlook
- 7.1.□Market Size & Forecast□
- 7.1.1.□By Value
- 7.2.□Market Share & Forecast
- 7.2.1.□By Disease Indication
- 7.2.2.□By End User
- 8.□Market Dynamics
- 8.1.□Drivers
- 8.2.□Challenges
- 9.□Market Trends & Developments
- 9.1.□Merger & Acquisition
- 9.2.□Product Development
- 9.3.□Recent Developments
- 10.□Policy & Regulatory Landscape
- 11.□Porters Five Forces Analysis
- 11.1.□Competition in the Industry
- 11.2.□Potential of New Entrants
- 11.3.□Power of Suppliers
- 11.4.□Power of Customers
- 11.5.□Threat of Substitute Products
- 12.□Canada Economic Profile
- 13.□Competitive Landscape
- 13.1.□Business Overview

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 13.2. □ Company Snapshot
- 13.3. □ Products & Services
- 13.4. □ Financials (As Reported)
- 13.5. □ Recent Developments
 - 13.5.1. □ Bristol-Myers Squibb Canada Co
 - 13.5.2. □ Pfizer Canada.
 - 13.5.3. □ Janssen Pharmaceuticals, Inc.
 - 13.5.4. □ Novartis Pharmaceuticals Canada Inc
 - 13.5.5. □ Merck & Co Inc.
 - 13.5.6. □ AstraZeneca Canada Inc.
 - 13.5.7. □ Sanofi-Aventis Canada Inc.
 - 13.5.8. □ Gilead Sciences Canada, Inc.
 - 13.5.9. □ Hoffmann-La Roche Limited.
- 14. □ Strategic Recommendations
- 15. □ About Us & Disclaimer

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Canada Cardiovascular Drugs Market, By Drug Classification (Branded, Generic), By Disease Indication (Hypertension, Coronary Artery Disease, Hyperlipidaemia, Arrhythmia, Others), By End User (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Others), By Region, Competition Forecast & Opportunities, 2028

Market Report | 2023-08-01 | 74 pages | TechSci Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$3500.00
	Multi-User License	\$4500.00
	Custom Research License	\$7500.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Date

2026-02-17

Signature



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com